Shares of immune-oncology cell therapy company 2seventy bio (NASDAQ:TSVT) are in focus today after it posted data from a Phase 1 study evaluating SC-DARIC33 for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also presented data associated with the evaluation of regulated IL-15 production in combination with DARIC33 activation for potency against AML.
SC-DARIC33 is a CAR T-cell therapy and in the study, its infusions were observed to be well tolerated without any dose-limiting toxicities. Further, the findings demonstrated that “Seattle Children’s proprietary iSynPro-regulated expression combined with rapamycin-controlled DARIC33 activation has the potential to enhance T cell function while preventing unrestrained T cell outgrowth.” The Phase 1 study is being led by Seattle Children’s Therapeutics.
Importantly, the therapy is a potentially first-in-class CD-33 targeting and regulatable CAR T cell therapy, and patient enrolment in the Phase 1 study remains ongoing.
TSVT shares have gained nearly 22.6% over the past month while short interest in the stock currently stands at nearly 17.8%.
Read full Disclosure